CRP/Albumin Ratio and Clotting in New AML Patients
Part of Blood & lymphatic, Cancer clinical trials.
This trial looks at how a simple blood test (CRP to Albumin ratio) relates to blood clotting problems in people newly diagnosed with Acute Myeloid Leukemia (AML). The goal is to better understand how the disease affects your body and find ways to monitor your health.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be newly diagnosed with Acute Myeloid Leukemia (AML).
- You must be treated at Assiut University Hospital.
- You cannot have Chronic Myeloid Leukemia (CML).
- You cannot have Acute Lymphoblastic Leukemia (ALL).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at special markers in bone marrow fluid to predict how well chemotherapy will work for newly diagnosed acute myeloid leukemia (AML). By identifying these markers early, doctors may be able to choose the best treatment plan for each patient.
This trial tests a new drug, CRD3874-SI, for people whose acute myeloid leukemia (AML) has returned or not responded to standard treatments. The goal is to see if this drug can help control the leukemia.
This study is looking at a substance called leptin in the blood of people with newly diagnosed acute myeloid leukemia (AML). The goal is to see if leptin levels can help doctors predict how well chemotherapy will work, which could guide better treatment choices.
This study looks at how your body weight (BMI) and blood fat levels (cholesterol and triglycerides) might affect how well treatment works for adults with newly diagnosed acute myeloid leukemia (AML). It could help doctors better understand factors that influence recovery.
This trial is checking a simple blood test—albumin levels—in people who have had a heart attack or unstable angina. It aims to see if albumin levels can give doctors useful information about your condition.
This study looks at two simple blood test markers (fibrinogen and albumin) to see if their ratio can help predict outcomes in people with newly diagnosed acute leukemia. It is a no-treatment study — just a blood draw at diagnosis to gather information.
Hear when a new AML trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.